Literature DB >> 445418

Active efflux of daunorubicin and adriamycin in sensitive and resistant sublines of P388 leukemia.

M Inaba, H Kobayashi, Y Sakurai, R K Johnson.   

Abstract

Significantly decreased uptake and retention of daunorubicin (DAU) and Adriamycin (ADR) have been reported in sublines of P388 leukemia resistant to these anthracyclines. We studied the effects of inhibitors of oxidative phosphorylation on uptake and retention of DAU and ADR in order to characterize the transport process for these anthracyclines and to clarify further the alteration in resistant cells. In glucose-free medium, uptake of DAU and ADR was accelerated by metabolic inhibitors to a greater extent in resistant cells than in sensitive cells. Under these conditions, drug uptake was similar in sensitive and resistant cells. When glucose was added to the incubation medium in the presence of 2,4-dinitrophenol, efflux of DAU from both sensitive and resistant cells was observed. Net efflux of ADR was also observed with the resistant cells, whereas glucose markedly inhibited 2,4-dinitrophenol-stimulated uptake of ADR by the sensitive cells. Furthermore, in sensitive and resistant cells preloaded with ADR and DAU, efflux of the drugs was inhibited by the addition of 2,4-dinitrophenol. These results suggest that there is an active outward transport mechanism for anthracyclines in P388 leukemia cells and that enhanced activity of this efflux process renders cells highly resistant to the cytostatic and cytotoxic effects of ADR and DAU.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 445418

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  89 in total

1.  A mathematical model of the P-glycoprotein pump as a mediator of multidrug resistance.

Authors:  S Michelson; D Slate
Journal:  Bull Math Biol       Date:  1992-11       Impact factor: 1.758

Review 2.  Resistance to cytostatic drugs at the cellular level.

Authors:  C P Vendrik; J J Bergers; W H De Jong; P A Steerenberg
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

3.  Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies.

Authors:  H Hamada; T Tsuruo
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

4.  Identification of members of the P-glycoprotein multigene family.

Authors:  W F Ng; F Sarangi; R L Zastawny; L Veinot-Drebot; V Ling
Journal:  Mol Cell Biol       Date:  1989-03       Impact factor: 4.272

5.  Uptake and metabolism of daunorubicin by human myelocytic cells.

Authors:  G Vasanthakumar; N K Ahmed
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

6.  Modulation of doxorubicin-toxicity by tamoxifen in multidrug-resistant tumor cells in vitro and in vivo.

Authors:  E Pommerenke; J Mattern; M Volm
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

7.  Cellular pharmacokinetics of aclacinomycin A in cultured L1210 cells. Comparison with daunorubicin and doxorubicin.

Authors:  A Zenebergh; R Baurain; A Trouet
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

8.  Contribution of drug transport and reductases to daunorubicin resistance in human myelocytic cells.

Authors:  G Vasanthakumar; N K Ahmed
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

9.  Comparative cytotoxicities of various morpholinyl anthracyclines.

Authors:  D G Streeter; D L Taylor; E M Acton; J H Peters
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

10.  Effect of verapamil on doxorubicin activity and pharmacokinetics in mice bearing resistant and sensitive solid tumors.

Authors:  F Formelli; L Cleris; R Carsana
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.